Developing medicines is a minefield that Tranzyme Pharma has navigated well so far. But the Durham company is about to embark on one of its trickiest missions.
Archive for September, 2009
Q&A with Sandy Kennedy
Thursday, September 10, 2009, 7:39 pm 1 Comment | Post a CommentSandy Kennedy is an executive at Quintiles Transnational, where she is charged with making sure that studies testing new medicines follow federal and industry regulations and guidelines.
Lenovo warehouse sale
Thursday, September 10, 2009, 11:44 am No Comments | Post a CommentLENOVO WAREHOUSE SALE
What: Lenovo Warehouse Sale
*Product listings will be provided upon arrival starting at 7:30am on sale day
When: Saturday, Sept. 12, 2009
Time: 8 a.m. to 3 p.m. (or while supplies last)
Where: Lenovo
1017 Think Place, Building 3
Morrisville, NC 27560
Who: Open to the Public
How: Cash, VISA and MasterCard only - Checks will not be accepted
From the mouths of innovators
Wednesday, September 9, 2009, 10:32 am No Comments | Post a CommentA new speakers’ series is starting Sept. 15 at Research Triangle Park headquarters with Moritz Beckmann, chief executive of XinRay Systems.
The series, which is open to members of the Triangle Area Research Directors Council, or TARDC, taps executives from RTP area companies and leading university researchers who are advancing technology in various fields including medicine, drug development and diagnostics.
A chance of showers
Tuesday, September 8, 2009, 6:42 pm No Comments | Post a CommentAnybody who moves to Raleigh, Durham or Chapel Hill from out-of-state realizes fairly quickly what a big deal the weather is around here.
The Research Triangle area is a watering hole for scientists of all stripes, but science is not what drives the local interest in rain or shine. No, it’s a healthy respect for some of the craziest weather patterns along the East Coast.
RTP Weekahead 9/8
Monday, September 7, 2009, 8:25 am No Comments | Post a CommentEvents taking place the week of Sept. 8 in the Research Triangle area that are open to the public:
RTP Wrapup 9/4
Thursday, September 3, 2009, 6:23 pm No Comments | Post a CommentA report offers hope that federal funds could become available for economic development in innovation hot spots such as the Research Triangle area, Bayer CropScience adds a research collaboration to recent efforts of creating better biotech seeds and Family Health International, a Durham organization that aims to improve public health worldwide, uses realty shows to stem the spread of HIV/AIDS.
Pharma gets creative to find patients for tests
Thursday, September 3, 2009, 9:59 am No Comments | Post a CommentFree health screenings, food and a raffle promise to draw a crowd Sept. 12 at North Carolina Central University.
There’s a reason for all the goodies. Organizers want people to stay and listen — to speakers like Dr. Robert Califf, who heads Duke University’s Clinical Research Institute; Dr. Wendy Brewster, director of women’s health research at the University of North Carolina at Chapel Hill; and executives from Quintiles Transnational and PPD, two North Carolina companies that help drugmakers test new medicines.
Next: A crucial decision
Thursday, September 3, 2009, 8:23 am 1 Comment | Post a CommentThis is the last part. Continued from part 2.
Getting a ghrelin drug to market
Thursday, September 3, 2009, 8:20 am No Comments | Post a CommentThis is the second part of three. Continued from part 1.
Work on promising ghrelin medicines has gotten to a critical stage a decade after Japanese researchers discovered the hormone that stimulates hunger and is linked to insulin production.
Ghrelin: A new hormone is found
Thursday, September 3, 2009, 8:15 am No Comments | Post a CommentINTRODUCTION
Tranzyme Pharma is one of dozens of drug development companies in North Carolina’s Research Triangle area, a biotech hot spot that is ranked third in the nation by number of companies. The Durham company has diligently advanced therapies based on a hormone that was discovered a decade ago, a technology also used by two rivals. Now, Tranzyme’s Board of Directors has to decide how to pay for the final development step and get its drugs to market: Go public, sell the company or go back to its investors hat in hand one more time.
This is the first part of three.
